PDCD1 and hepatocellular carcinoma: Programmed death receptor-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors, such as nivolumab and pembrolizumab, have been conditionally approved by the US Food and Drug Administration for second-line treatment of advanced HCC (4, 22).